美国血液学会2021年镰状细胞病指南:造血干细胞移植
美国血液学会(ASH)组织多学科专家组,基于截至2019年的系统证据评价,采用GRADE方法制定了镰状细胞病(SCD)造血干细胞移植(HSCT)的循证指南。专家组就HSCT的时机和类型达成8条推荐,但证据回顾未发现随机对照试验,所有推荐均基于极低确定性证据。关键推荐包括对早期出现神经系统损伤或反复急性胸部综合征者考虑HSCT,并改进非清髓性预处理方案。
要点
- 对早期出现神经系统损伤或反复急性胸部综合征的SCD患者,应考虑HSCT。
- 需改进非清髓性预处理方案以提高HSCT适用性。
- 所有推荐均基于极低确定性证据,无随机对照试验支持。
核心结论
- 专家组就SCD患者HSCT的时机和类型达成8条推荐。
- 证据回顾未发现HSCT在SCD中的随机对照临床试验,所有推荐基于极低确定性证据。
- 关键推荐包括对早期神经系统损伤或反复急性胸部综合征者考虑HSCT,并改进非清髓性预处理方案。
研究设计与样本
- ASH成立多学科指南专家组,包括2名患者代表,并平衡利益冲突。
- Mayo循证实践研究项目支持指南制定,包括截至2019年的系统证据评价。
- 专家组采用GRADE方法(含Evidence-to-Decision框架)评估证据并形成推荐,推荐草案接受公众评论。
主要发现
- 专家组达成8条推荐,帮助评估SCD个体应考虑HSCT的时机和类型。
- 证据评价未发现HSCT在SCD中的随机对照临床试验。
关键数值与推荐
- 对早期出现神经系统损伤或反复急性胸部综合征的SCD患者,考虑HSCT。
- 改进非清髓性预处理方案。
- 所有推荐均基于极低确定性证据。
临床怎么用
- 临床医生可依据8条推荐评估SCD患者HSCT的时机和类型。
- 对早期神经系统损伤或反复急性胸部综合征患者,应考虑HSCT。
- 应关注并改进非清髓性预处理方案。
局限性
- 证据回顾未发现HSCT在SCD中的随机对照临床试验,所有推荐基于极低确定性证据。
- 未来研究应建立稳健的SCD登记库,作为HSCT研究的对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sickle cell disease (SCD) is a life-limiting inherited hemoglobinopathy that results in significant complications and affects quality of life. Hematopoietic stem cell transplantation (HSCT) is currently the only curative intervention for SCD; however, guidelines are needed to inform how to apply HSCT in clinical practice. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and health professionals in their decisions about HSCT for SCD. METHODS: The multidisciplinary guideline panel formed by ASH included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews (through 2019). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 8 recommendations to help patients and providers assess how individuals with SCD should consider the timing and type of HSCT. CONCLUSIONS: The evidence review yielded no randomized controlled clinical trials for HSCT in SCD; therefore, all recommendations are based on very low certainty in the evidence. Key recommendations include considering HSCT for those with neurologic injury or recurrent acute chest syndrome at an early age and to improve nonmyeloablative regimens. Future research should include the development of a robust SCD registry to serve as a comparator for HSCT studies.
引用
- Kanter J, Liem RI, Bernaudin F, et al. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. Blood Adv. 2021. PMID: 34581773. doi:10.1182/bloodadvances.2021004394C
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。